Contact Us • Home

Clinical Trials >> Melanoma >> SUAVE >> Treatment

Treatment/Intervention

To compare the progression free survival time, overall response rate, and adverse events of Sunitinib with Dacarbazine.

Patients will be randomised equally between the two arms:

  • Control arm Dacarbazine: Patients will receive 1000mg/m� by IV infusion every 21 days until progression or unacceptable toxicity
  • Experimental arm Sunitinib: Patients will take 50mg Sunitinib capsules once a day for 28 days followed by a 14 day break until progression or unacceptable toxicity

Patients will attend clinic visits every 3 weeks and undergo medical imaging every 12 weeks.
Patients will continue to be followed up after they have stopped treatment (if they maintain consent to do so). At first progression of disease, patients may be eligible to crossover to the other study treatment.


Information | Treatment | Endpoints | Eligibility | Sites - Open | Sites - Interested | Map of Sites | FAQ | Links |

Admin/Site Area

Username:
Password:
Forgotten Password


"The experience and treatment I received at the Royal Liverpool Hospital was so fantastic that I had to tell the people involved with my treatment how marvelous they were, so please would you pass on my thanks and gratitude to Professor Neoptolemos and his team of surgeons, the wonderful doctors and nursing staff" - Anon (Participant in ESPAC-3(v2) trial)

Read more Patient stories